New Delhi: Sharda University has announced successful research in collaboration with Nanoved Research Foundation. clinical trials Of horse farmA nanotechnology-based nutraceutical designed for safety of the smokers’ Keeps lungs healthy by significantly reducing carbon monoxide (CO) levels. This breakthrough formulation uses Curcumina compound derived from turmeric, and offers a promising preventive measure against Smoking-Related IllnessesThe announcement comes on the occasion of World No Tobacco Day, which underlines the urgent need for effective interventions to stop smoking and protect lung health.

Cigarette smoking remains a major cause of lung cancer and other chronic diseases, with statistics showing that it accounts for 90 percent of lung cancer cases in men and 70-80 percent of cases in women. Smokers are 15 to 30 times more likely to develop lung cancer or die from it than non-smokers. Keeping this in mind, Dr. Vijay Kanuru, founder of Nanoved Research Foundation, has developed the curcumin-based nutraceutical HARAS, which claims to have enhanced bioavailability through innovative bioavailability. Nano,

The clinical trials conducted by Sharda University researchers including Dr. Deepak Bhargava, Dr. Vidya Devi Chandavarkar and Dr. Mithilesh Mishra involved 25 healthy smoking volunteers who were given 10 ml of Haras juice daily for 30 days. CO levels were carefully monitored using a breath analyser at the start, mid-point and end of the trial. The results showed that there was a statistically significant reduction in CO levels by the 30th day (P
Dr Deepak Bhargava, Professor and Head, Department of Oral Pathology and Microbiology, Sharda University, said, “Our clinical studies show that HARAS provides substantial benefits Lung protection It is a very useful drug for smokers by significantly reducing carbon monoxide levels. This nutraceutical is an important tool in combating the adverse health effects of smoking.”

Dr. Mithilesh Mishra, Associate Professor, Sharda University, said, “In our detailed study with 100 smoking patients, HARAS did not show any side effects while there was a significant reduction in CO levels, confirming its safety and efficacy.”

Dr. Kanuru said, “Using liposomal nanotechnology, we have significantly improved the bioavailability of curcumin, allowing even smaller doses to provide significant health benefits. HARAS is not only beneficial for smokers but also provides protection against air pollution-induced conditions such as fatigue, inflammation, and cardiovascular problems.”

Dr. Pradyut Waghre, Pulmonologist, Apollo Hospitals Hyderabad, said, “HARAS’ ability to reduce lung inflammation and oxidative stress caused by cigarette smoke makes it an important preventive measure for millions of smokers.”

HARAS works by leveraging the powerful antioxidant and anti-inflammatory properties of curcumin. Curcumin effectively reduces inflammatory signals and oxidative stress caused by cigarette smoke, thereby protecting lung tissue. The proprietary nanoformulation ensures that curcumin is efficiently absorbed by the body, thereby maximizing its therapeutic effects.

The development and successful validation of HARAS represents a major advance in preventive healthcare. By significantly reducing CO levels in smokers, HARAS may help reduce the risk of lung cancer and other smoking-related diseases. This nutraceutical offers a non-invasive, safe, and effective approach to improve lung health and reduce healthcare burden. HARAS is particularly beneficial for marginalized populations, providing an accessible solution to combat the harmful health effects of smoking and air pollution. The announcement of these findings on World No Tobacco Day underscores the urgent need for innovative solutions to address global tobacco-related health challenges.

The innovative and clinically validated HARAS formula is available in two convenient forms: over-the-counter (OTC) as a liquid juice and by prescription as a capsule. This dual availability ensures that HARAS can be easily accessed by a wide range of individuals. General practitioners and pulmonologists can prescribe HARAS capsules, making it a versatile addition to treatment plans aimed at reducing the harmful effects of smoking.